FDA Authorized Johnson & Johnson Robotic Surgery System

The clearance of the OTTAVA system allows medical providers to utilize new table-integrated technology for ten general surgeries.

Updated on Oct. 13, 2026 in Healthcare

FDA Authorized Johnson & Johnson Robotic Surgery System

Live Poll

Do you believe major medical technology innovations generally lead to better patient outcomes in your area?

In July 2026, the FDA granted de novo authorization to Johnson & Johnson for its OTTAVA robotic system, a platform designed for soft tissue procedures. This regulatory milestone accompanies the company reporting $25.4 billion in sales for the third quarter of 2026.

Why it matters

The authorization expands the landscape for hospital capital equipment procurement by introducing a new, data-integrated robotic option for general surgeons. It follows a period of stable growth across the company's MedTech and Innovative Medicine divisions.

Johnson & Johnson reported $25.4 billion in quarterly sales, marking a 5.9% increase, and now forecasts full-year 2026 operational sales growth between 6.7% and 7.1%. The firm currently maintains 29 products and platforms that generate at least $1 billion in annual revenue.

The players

Johnson & Johnson

A global healthcare conglomerate operating through MedTech and Innovative Medicine divisions.

FDA

The federal agency responsible for the regulatory authorization of medical devices and pharmaceutical products.

The details

The OTTAVA system utilizes a table-integrated design specifically engineered for soft tissue robotic surgery. It connects to the company's Polyphonic digital ecosystem, enabling providers to pull procedure data insights into clinical workflows. The FDA authorization covers 10 general surgery procedures, including gastric bypass and hiatal hernia repair.

July 2026: FDA granted de novo authorization to the OTTAVA system.
July 29, 2026: Previous guidance for sales growth was issued.
Q3 2026: Reported sales reached $25.4 billion.
Full-year 2026: The company expects to exceed $100 billion in total revenue.

Market Landscape

This authorization follows the established FDA de novo regulatory framework for medical devices lacking a direct, substantially equivalent predicate. It marks a significant expansion for the manufacturer's MedTech segment, which recently reported a 2.5% increase in operational sales growth.

Operators in the surgical and hospital procurement space should monitor the rollout of the OTTAVA system to evaluate its impact on facility throughput and capital expenditure requirements. Management should also factor the company's 6.7% to 7.1% projected operational sales growth into their own long-term supply chain and vendor stability assessments.

The takeaway

The addition of a data-integrated robotic surgery platform represents a major competitive pivot in the MedTech market. Operators should watch for shifts in market share among surgical robotics providers as the company leverages its digital ecosystem, Polyphonic, to drive long-term adoption.